Modulation of cystic fibrosis lung disease by variants in interleukin-8

被引:51
作者
Hillian, A. D. [1 ]
Londono, D. [2 ]
Dunn, J. M. [3 ]
Goddard, K. A. B. [2 ]
Pace, R. G. [4 ]
Knowles, M. R. [4 ]
Drumm, M. L. [1 ,3 ]
机构
[1] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA
[3] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA
[4] Univ N Carolina, Cyst Fibrosis Pulm Res Treatment Ctr, Chapel Hill, NC USA
关键词
cystic fibrosis; genetic modifier; interleukin-8; pulmonary;
D O I
10.1038/gene.2008.42
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cystic fibrosis pulmonary disease is characterized by excessive and prolonged inflammation. CF Pulmonary disease severity exhibits considerable variation that, to some extent, appears to be due to the presence of modifier genes. Several components of the inflammatory response are known to have altered regulation in the CF lung. Genetic variants in 52 inflammatory genes were tested for associations with lung disease indices in a CF patient population (n = 737) homozygous for the Delta F508 cystic fibrosis transmembrane conductance regulator mutation. Variants in three inflammatory genes showed significant genotypic associations with CF lung disease severity, including IL8 and previously reported TGF beta 1 (P <= 0.05). When analyzed by gender, it was apparent that IL8 variant associations were predominantly due to males. The IL8 variants were tested in an additional CF population (n = 385) and the association in males verified (P <= 0.01). The IL8 variants were in strong linkage disequilibrium with each other (R-2 >= 0.82), while variants in neighboring genes CXCL6, RASSF6 and PF4V1 did not associate (P >= 0.26) and were in weaker LD with each other and with the IL8 variants (0.01 <= R-2 <= 0.49). Studies revealed differential expression between the IL8 promoter variant alleles (P < 0.001). These results suggest that IL8 variants modify CF lung disease severity and have functional consequences.
引用
收藏
页码:501 / 508
页数:8
相关论文
共 50 条
  • [41] Vitamin D and Cystic Fibrosis Lung Disease
    Loukou, Ioanna
    Boutopoulou, Barbara
    Fouzas, Sotirios
    Douros, Konstantinos
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2015, 15 (12) : 974 - 983
  • [42] Emerging therapies for cystic fibrosis lung disease
    Grasemann, Hartmut
    Ratjen, Felix
    EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (04) : 653 - 659
  • [43] Emerging therapies for cystic fibrosis lung disease
    Rubin, BK
    CHEST, 1999, 115 (04) : 1120 - 1126
  • [44] Update on pathogenesis of cystic fibrosis lung disease
    Donaldson, SH
    Boucher, RC
    CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (06) : 486 - 491
  • [45] Innate immunity in cystic fibrosis lung disease
    Hartl, D.
    Gaggar, A.
    Bruscia, E.
    Hector, A.
    Marcos, V.
    Jung, A.
    Greene, C.
    McElvaney, G.
    Mall, M.
    Doering, G.
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (05) : 363 - 382
  • [46] Lung disease modifier genes in cystic fibrosis
    Guillot, Loic
    Beucher, Julie
    Tabary, Olivier
    Le Rouzic, Philippe
    Clement, Annick
    Corvol, Harriet
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2014, 52 : 83 - 93
  • [47] Role of corticosteroids in cystic fibrosis lung disease
    BalfourLynn, IM
    Dinwiddie, R
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1996, 89 : 8 - 13
  • [48] Cystic Fibrosis Lung Disease in the Aging Population
    Kunzi, Lisa
    Easter, Molly
    Hirsch, Meghan June
    Krick, Stefanie
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [49] Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas
    Ivarsson, K
    Ekerydh, A
    Fyhr, IM
    Janson, PO
    Brännström, M
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2000, 79 (09) : 777 - 784
  • [50] Cystic fibrosis lung disease: Current perspectives
    Jung, Jin-A
    ALLERGY ASTHMA & RESPIRATORY DISEASE, 2020, 8 (01): : 3 - 8